<DOC>
	<DOCNO>NCT01343888</DOCNO>
	<brief_summary>The objective trial evaluate efficacy safety two different treatment regimen BI 201335 , combination PegIFN/RBV ) compare standard care ( SOC ) PegIFN/RBV alone .</brief_summary>
	<brief_title>Efficacy Safety BI 201335 ( Faldaprevir ) Combination With Pegylated Interferon-alpha Ribavirin Treatment-naïve Genotype 1 Hepatitis C Infected Patients ( STARTverso 1 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C infection , diagnose positive antiHCV antibody detect HCV RNA screen addition : 1. positive antiHCV antibody detect HCV RNA least 6 month prior screen ; , 2. liver biopsy consistent chronic HCV infection . 2 . HCV genotype 1 infection confirm genotypic test screening . 3 . Therapynaïve interferon , pegylated interferon , ribavirin antiviral / immunomodulatory drug acute chronic HCV infection . 4 . HCV RNA = 1,000 IU/mL screen 5 . Documentation liver biopsy within 3 year fibroscan within 6 month prior randomization . Note : If cirrhosis previously demonstrate biopsy , biopsy obtain 3 year randomization need repeat . Biopsies may waive patient would place risk procedure . Inability liver biopsy patient risk procedure exclude patient trial . 6 . Age 18 70 year 7 . Female patient : 1. document hysterectomy , 2. ovary remove , 3. document tubal ligation , 4. postmenopausal last menstrual period least 12 month prior screen , 5. childbearing potential negative serum pregnancy test screen Day 1 , , sexually active , agree use one appropriate medically accept method birth control date screen 7 month last dose ribavirin addition consistent correct use condom . Patients must agree breastfeed time date screen 7 month last dose ribavirin . Medically accept method contraception females trial ethinyl estradiol contain contraceptive , diaphragm spermicide substance intrauterine device . Male patient : 1. document sterile , 2. without pregnant female partner ( ) consistently correctly use condom female partner ( ) ( childbearing potential ) use one appropriate medically accept method birth control date screen 7 month last dose ribavirin . It responsibility male patient ensure partner ( ) pregnant prior screening study become pregnant treatment observation phase . Female partner childbearing potential perform monthly pregnancy test date screen 7 month last dose ribavirin ( test provide sponsor ) . 8 . Signed informed consent form prior trial participation Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screen 2 . Evidence acute chronic liver disease due cause chronic HCV infection . Incidental steatosis diagnose biopsy exclusion criterion . 3 . HIV coinfection 4 . Hepatitis B virus ( HBV ) infection base presence HBsAg 5 . Active malignancy , history malignancy within last 5 year prior screen ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) 6 . Active , history alcohol illicit drug abuse cannabis within past 12 month 7 . A condition define one opinion investigator may put patient risk participation study , may influence result study , limit patient ability participate study 8 . Usage investigational drug within 30 day prior screen , plan usage investigational drug course study . 9 . Received concomitant systemic antiviral , hematopoietic growth factor , immunomodulatory treatment within 30 day prior randomization . Patients treat oral antiviral acyclovir , famciclovir valacyclovir recurrent herpes simplex infection ; oseltamivir zanamivir influenza A infection , may screen . 10 . Received silymarin ( milk thistle ) , glycyrrhizin , Shosaikoto ( SST ) within 28 day prior randomization throughout treatment phase trial . 11 . Known hypersensitivity ingredient study drug . 12 . Alpha fetoprotein value &gt; 100 ng/mL screening ; &gt; 20 ng/mL = 100 ng/mL , patient may include evidence liver cancer appropriate imaging study ( e.g. , ultrasound , CT scan , MRI ) within last 6 month prior randomization ( Visit 2 ) . Other exclusion criterion relate pegylated interferon and/or ribavirin restriction list .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>